CARBIDOPA- carbidopa tablets tablet

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

carbidopa (UNII: MNX7R8C5VO) (carbidopa anhydrous - UNII:KR87B45RGH)

から入手可能:

Oceanside Pharmaceuticals

INN（国際名）:

carbidopa

構図:

carbidopa anhydrous 25 mg

投与経路:

ORAL

処方タイプ:

PRESCRIPTION DRUG

適応症:

Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from the addition of c

製品概要:

Carbidopa Tablets, 25 mg, are round, orange-colored compressed tablets that are on one side flat beveled edge, bisect, embossed “711” and embossed “LODOSYN” on the other side. They are supplied as follows: NDC 68682-200-25 bottles of 100. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

認証ステータス:

New Drug Application Authorized Generic

製品の特徴

CARBIDOPA- CARBIDOPA TABLETS TABLET
OCEANSIDE PHARMACEUTICALS
----------
CARBIDOPA
TABLETS
WHEN CARBIDOPA IS TO BE GIVEN TO CARBIDOPA-NAIVE PATIENTS WHO ARE
BEING TREATED WITH LEVODOPA,
THE TWO DRUGS SHOULD BE GIVEN AT THE SAME TIME, STARTING WITH NO MORE
THAN 20 TO 25% OF THE
PREVIOUS DAILY DOSAGE OF LEVODOPA WHEN GIVEN WITHOUT CARBIDOPA. AT
LEAST TWELVE HOURS SHOULD
ELAPSE BETWEEN THE LAST DOSE OF LEVODOPA AND INITIATION OF THERAPY
WITH CARBIDOPA AND LEVODOPA.
SEE THE WARNINGS AND DOSAGE AND ADMINISTRATION SECTIONS BEFORE
INITIATING THERAPY.
DESCRIPTION
Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a
white, crystalline compound,
slightly soluble in water, with a molecular weight of 244.3. It is
designated chemically as (–)-L-α-
hydrazino-α-methyl-β-(3,4-dihydroxybenzene) propanoic acid
monohydrate. Its empirical formula is
C
H N O •H O, and its structural formula is:
Carbidopa tablets contain 25 mg of carbidopa. Inactive ingredients are
microcrystalline cellulose,
FD&C Yellow No. 6, magnesium stearate and pregelatinized starch.
Tablet content is expressed in terms of anhydrous carbidopa which has
a molecular weight of 226.3.
CLINICAL PHARMACOLOGY
Parkinson’s disease is a progressive, neurodegenerative disorder of
the extrapyramidal nervous system
affecting the mobility and control of the skeletal muscular system.
Its characteristic features include
resting tremor, rigidity, and bradykinetic movements. Symptomatic
treatments, such as levodopa
therapies, may permit the patient better mobility.
MECHANISM OF ACTION
Current evidence indicates that symptoms of Parkinson’s disease are
related to depletion of dopamine in
the corpus striatum. Administration of dopamine is ineffective in the
treatment of Parkinson’s disease
apparently because it does not cross the blood-brain barrier. However,
levodopa, the metabolic
precursor of dopamine, does cross the blood-brain barrier, and
presumably is converted to dopamine in
the brain. This is thought to be the mechanism whereby levodopa
relieve